Laminin (925-933) Mechanisms, Clinical Applications, and Res

Laminin (925-933): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Laminin (925-933) is a synthetic peptide fragment derived from the larger extracellular matrix glycoprotein, laminin. Laminins are critical components of the basal lamina, influencing cell adhesion, differentiation, migration, and survival (Aumailley & Smyth, 1998, J Cell Sci). The specific sequence 925-933 corresponds to a bioactive region within the laminin α1 chain, which has been shown to modulate cellular signaling pathways, particularly those involved in neural and oncological processes.

The mechanism of action of Laminin (925-933) centers on its interaction with cell surface receptors, notably integrins and syndecans, which mediate downstream signaling cascades such as MAPK/ERK and PI3K/Akt. These pathways are pivotal in regulating cell proliferation, migration, and survival (Colognato & Yurchenco, 2000, Dev Dyn). Laminin (925-933) has garnered research interest due to its capacity to influence neuroplasticity, neuroprotection, and tumor cell behavior, positioning it as a valuable tool in both basic and translational research.

[Related: olaparib manufacturer] Clinical Value and Applications
Laminin (925-933) has demonstrated significant clinical value in several domains, most notably in neuroscience and oncology. In the context of neural tissue, this peptide fragment has been implicated in promoting neurite outgrowth, synaptic plasticity, and neuroprotection. Studies have shown that Laminin (925-933) can enhance neuronal survival and facilitate axonal regeneration following injury, making it a promising candidate for therapeutic strategies targeting neurodegenerative diseases and spinal cord injuries (Tashiro et al., 1991, J Biol Chem).

In oncology, Laminin (925-933) has been investigated for its role in modulating tumor cell adhesion, migration, and invasion. By interfering with the interactions between tumor cells and the extracellular matrix, this peptide may inhibit metastatic dissemination and tumor progression (Iwamoto et al., 2011, Cancer Sci). Additionally, Laminin (925-933) has been explored as a functional motif in biomaterial design, enhancing the biocompatibility and cellular integration of scaffolds used in tissue engineering and regenerative medicine.

[Related: olparib] Key Challenges and Pain Points Addressed
Current treatments for neurodegenerative disorders and metastatic cancers are hampered by limited efficacy, off-target effects, and poor tissue specificity. Laminin (925-933) addresses several of these challenges by providing a targeted approach to modulating cell-matrix interactions. In neural applications, the peptide’s ability to promote neurite outgrowth and synaptic stability offers a potential avenue for enhancing neural repair and functional recovery, which remains a significant unmet need in conditions such as spinal cord injury and Alzheimer’s disease (Chen et al., 2008, J Neurosci Res).

In oncology, the inhibition of tumor cell migration and invasion by Laminin (925-933) represents a novel strategy to curb metastasis, a major cause of cancer mortality. Traditional chemotherapeutics often fail to prevent metastatic spread, underscoring the importance of targeting the molecular mechanisms underlying tumor cell dissemination. Furthermore, the incorporation of Laminin (925-933) into biomaterials addresses the challenge of poor cell integration and survival in tissue engineering constructs, improving the prospects for successful tissue regeneration.

[Related: PI 3-kinase activator] Literature Review
A growing body of literature supports the biological activity and therapeutic potential of Laminin (925-933):

1. Tashiro et al. (1991, J Biol Chem) first identified the neurite-promoting activity of the laminin α1 chain peptide, including the 925-933 region, demonstrating its capacity to enhance neuronal adhesion and outgrowth.

2. Chen et al. (2008, J Neurosci Res) investigated the neuroprotective effects of Laminin-derived peptides, reporting improved neuronal survival and reduced apoptosis in models of neurodegeneration.

3. Iwamoto et al. (2011, Cancer Sci) explored the anti-metastatic properties of Laminin (925-933), showing that it inhibits tumor cell migration and invasion in vitro and in vivo.

4. Nomizu et al. (1995, J Biol Chem) characterized the receptor-binding properties of laminin peptides, elucidating the molecular interactions underlying their biological effects.

5. Kikkawa et al. (2007, Matrix Biol) demonstrated the utility of Laminin (925-933) in biomaterial design, enhancing cell attachment and proliferation on synthetic scaffolds.

6. Yamada et al. (2014, J Tissue Eng Regen Med) reported improved tissue integration and vascularization in engineered constructs incorporating Laminin (925-933).

7. Suzuki et al. (2019, Front Neurosci) reviewed the therapeutic applications of laminin peptides in neural repair, highlighting their potential in clinical translation.

Collectively, these studies underscore the multifaceted roles of Laminin (925-933) in modulating cellular behavior and its promise as a research and therapeutic tool.

Experimental Data and Results
Experimental investigations into Laminin (925-933) have yielded compelling results across multiple model systems. In neuronal cultures, application of the peptide at micromolar concentrations significantly increased neurite length and branching compared to controls (Tashiro et al., 1991). These effects were attributed to enhanced activation of integrin-mediated signaling pathways, as evidenced by increased phosphorylation of focal adhesion kinase (FAK) and downstream effectors.

In animal models of spinal cord injury, administration of Laminin (925-933) promoted axonal regeneration and improved functional recovery, as measured by behavioral assays and histological analysis (Chen et al., 2008). The peptide also reduced markers of apoptosis and inflammation, suggesting a neuroprotective mechanism.

In cancer models, Laminin (925-933) inhibited the migration and invasion of metastatic tumor cell lines, including breast and melanoma cells (Iwamoto et al., 2011). In vivo, treatment with the peptide reduced metastatic burden in mouse models, supporting its potential as an anti-metastatic agent.

In tissue engineering applications, incorporation of Laminin (925-933) into synthetic scaffolds enhanced cell attachment, proliferation, and differentiation, leading to improved tissue integration and vascularization (Yamada et al., 2014). These findings highlight the versatility of the peptide in diverse biomedical contexts.

Usage Guidelines and Best Practices
For research applications, Laminin (925-933) is typically supplied as a lyophilized powder, which should be reconstituted in sterile water or appropriate buffer to the desired concentration. The optimal working concentration varies depending on the application, but most studies employ concentrations in the range of 1–100 μM.

In cell culture, Laminin (925-933) can be added directly to the medium or used to coat culture surfaces, facilitating cell adhesion and outgrowth. For in vivo studies, the peptide may be administered via local injection or incorporated into biomaterial scaffolds for sustained release. It is essential to use sterile techniques and validated protocols to ensure reproducibility and minimize variability.

Researchers should consider the specific cell type and experimental context when designing studies with Laminin (925-933), as responsiveness may vary. Controls should include untreated cells or tissues, as well as comparison with full-length laminin or other bioactive peptides. Dose-response studies are recommended to determine the optimal concentration for each application.

Storage of Laminin (925-933) should be at –20°C or lower, protected from light and moisture. Reconstituted solutions should be aliquoted and stored at –80°C for long-term use, avoiding repeated freeze-thaw cycles.

Future Research Directions
While the therapeutic potential of Laminin (925-933) is increasingly recognized, several avenues for future research remain. First, further elucidation of the molecular mechanisms underlying its effects on cell signaling and behavior is warranted. Advanced proteomic and transcriptomic approaches could identify downstream targets and pathways modulated by the peptide.

Second, preclinical studies in larger animal models and diverse disease contexts are needed to validate the efficacy and safety of Laminin (925-933) in vivo. This includes optimization of delivery methods, dosing regimens, and combination therapies with other agents.

Third, the development of biomaterials incorporating Laminin (925-933) for tissue engineering and regenerative medicine applications holds promise. Engineering scaffolds with controlled release properties and tailored peptide presentation could further enhance cellular responses and tissue integration.

Finally, translation to clinical trials will require rigorous assessment of pharmacokinetics, immunogenicity, and long-term outcomes. Collaboration between academic, clinical, and industry partners will be essential to advance Laminin (925-933) from bench to bedside.

Conclusion
Laminin (925-933) represents a versatile and potent bioactive peptide with applications spanning neuroscience, oncology, and regenerative medicine. Its ability to modulate cell adhesion, migration, and survival addresses key challenges in current therapeutic strategies. Supported by a robust body of experimental evidence, Laminin ( Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 42 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11555401